An Open-Label, Three-Cohort, Phase 2 Study of E7080 (Lenvatinib) in Subjects With Recurrent Malignant Glioma

Trial Profile

An Open-Label, Three-Cohort, Phase 2 Study of E7080 (Lenvatinib) in Subjects With Recurrent Malignant Glioma

Completed
Phase of Trial: Phase II

Latest Information Update: 30 May 2016

At a glance

  • Drugs Lenvatinib (Primary) ; Bevacizumab
  • Indications Glioblastoma; Glioma
  • Focus Therapeutic Use
  • Sponsors Eisai Co Ltd
  • Most Recent Events

    • 20 May 2016 Status changed from discontinued to completed.
    • 27 Dec 2013 Actual study completion date added as reported by ClinicalTrials.gov record.
    • 26 Dec 2013 Status changed from active, no longer recruiting to discontinued, as per ClinicalTrials.gov..
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top